Jubilant Ingrevia Limited engages in the life science products and solutions in India, the United States, Europe, China and internationally. It operates in three segments: Specialty Chemicals, Nutrition & Health Solutions, and Chemical Intermediates. The Specialty Chemicals segment offers bio-pyridine and -picolines, fine chemicals, agro chemicals, custom development and manufacturing services, and microbial control solutions. The Nutrition & Health Solutions segment provides nutrition and health ingredients; and animal and human nutrition health solutions. The Chemical intermediates segment offers acetyls and specialty ethanol. The company provides piperidines, metal complexes, choline salts, vitamin B3, Vitamin B4, picolinates, riboflavin phosphate sodium, nutritional premixes, antioxidants, straight ingredients, acetic anhydride, acetic acid, ethyl acetate, propionic anhydride, formaldehyde, bio acetic acid-food grade, acetaldehyde, and ethanol, as well as cyano, acetyl, amino, halo, alkyl, and aldehyde pyridines. In addition, it offers route design, process development, process optimization, and scale-up and commercial manufacturing of intermediates. Further, the company provides vitamins, mineral premixes, stress regulator, amino acid, herbal choline, herbal non-antibiotic growth promoter and egg quality enhancer, toxin binder, acidifiers, and enzymes and emulsifiers. It serves pharmaceutical, animal and human nutrition, agrochemical, personal and consumer care, and industrial customers. The company was formerly known as Jubilant LSI Limited and changed its name to Jubilant Ingrevia Limited in October 2020. Jubilant Ingrevia Limited was incorporated in 2019 and is headquartered in Noida, India.
Revenue projections:
Revenue projections for JUBLINGREA The projected decline in JUBLINGREA's revenues compared to last year is expected to make investors cautious. A drop in revenue often has a direct negative effect on the company's bottom line, signaling potential challenges that could undermine investor confidence and reduce overall profitability.
Financial Ratios:
currentRatio
0.000000
forwardPE
26.853931
debtToEquity
26.094000
earningsGrowth
0.542000
revenueGrowth
0.013000
grossMargins
0.393090
operatingMargins
0.097600
trailingEps
17.510000
forwardEps
0.000000
JUBLINGREA's Forward PE ratio is favorable, indicating that the stock price is well-positioned in relation to its earnings. It is not overpriced, leaving room for growth, which makes it a solid option for investors seeking both stability and future appreciation. JUBLINGREA's Debt-to-Equity ratio is low, indicating the company is not over-leveraged. This suggests a prudent approach to financing, with minimal dependence on debt, reducing the financial risk associated with high leverage, and signaling a stable financial outlook.
Price projections:
Price projections for JUBLINGREA Jubilant Ingrevia Limited's price projections have been revised higher over time, reflecting increased confidence in the company's future potential. This steady upward trend suggests analysts expect Jubilant Ingrevia Limited to continue its positive trajectory.
Recommendation changes over time:
Recommendations trend for JUBLINGREA
Jubilant Ingrevia Limited has received a favorable buy bias from analysts recently, positioning it as a solid investment opportunity. This sentiment may attract more investors, who view Jubilant Ingrevia Limited as a stable option to park their money and potentially benefit from the company's continued growth and profitability.
DISCLAIMER: We provide information and our musings based on events, but nothing on this site can be considered professional advice of any kind.
The article discusses the implications of the Eurozone CPI at 2.1% regarding...
By clicking "Accept", you agree to the storing of cookies on your device to enhance site navigation, analyze site usage and assist in our tailored marketing efforts.